My mum has NSCLC grade 3b and is now moving to second-line treatment after the immunotherapy/chemo combination failed to work after an initial good response. Last week she had radiotherapy to the main tumour to help reduce the size and treat her breathlessness and hoarse voice. She is now heavily fatigued since the radiotherapy.
We met with her oncologist yesterday who was at pains to state that further treatment may not prolong life much more and may in fact cause more harm in terms of quality of life. Mum is very aware of this, but still wants to give it a go. She has said that if treatment becomes too much, she will stop.
During the meeting it was agreed that mum would go on to docetaxel. I asked him about adding in nintedanib and, although he isn't convinced it will add much benefit, he has agreed to mum having it.
When I got home I did some more research and after reading several forums and other documents I came across evidence and people who have been given Erlotinib/Tarceva despite being EGFR negative and had very good results. I also found this quote:
“A TKI should be strongly considered for all patients in the second-line, third-line, or maintenance setting, including those patients who are EGFR negative and who may not have the clinical predictors of outcome previously reported”.
Is there anyone who can advise me on whether this is something my mum can ask for? She is NGFR negative so I assumed targeted therapy would never be offered. I would consider private if it meant she could at least trial it.
I'd really appreciate your thoughts on this.